SCHEMBL8360539

SCHEMBL8360539

COC(=O)c1ccc2c(-c3ccccc3)cn(C(=O)C(F)(F)F)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.46
EGFR P00533 1/20 0.45
PTGS2 P35354 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
KDM4E B2RXH2 1/20 0.43
MAPT P10636 1/20 0.43
RECQL P46063 1/20 0.43
PLEC Q15149 1/20 0.43
LDHA P00338 1/20 0.43
SCN5A Q14524 2/20 0.43
PDK2 Q15119 3/20 0.42
ALDH1A1 P00352 2/20 0.41
GLA P06280 1/20 0.41
HPGD P15428 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KIF11 P52732 1/20 0.40
DGAT2 Q96PD7 1/20 0.40
NEK1 Q96PY6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL173901 0.88 SCN9A (0.49) SCN9AEGFRPTGS2MEN1KMT2A
SCHEMBL146186 0.84 SCN9A (0.44) SCN9AEGFRPTGS2MEN1KMT2A
SCHEMBL146859 0.81 SCN9A (0.66) SCN9AEGFRPTGS2TDP1SCN5A
SCHEMBL8478993 0.79 HTT (0.50) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL8480214 0.78 KMT2A (0.57) EGFRMEN1KMT2AKDM4EMAPT
SCHEMBL4326615 0.77 SCN9A (0.49) SCN9AEGFRPTGS2MEN1KMT2A
SCHEMBL150993 0.76 SCN9A (0.52) SCN9AKDM4ESCN5ADGAT2
SCHEMBL13577941 0.75 ASH1L (0.48) SCN9AEGFRPTGS2MEN1KMT2A
SCHEMBL145542 0.75 PTGS1 (0.45) SCN9AEGFRMEN1KMT2AKDM4E
Hydrochloric Acid SCHEMBL4326712 0.74 ASH1L (0.47) SCN9AEGFRPTGS2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324011-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324011-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA SCN9A 775/4885EGFR 3875/4885PTGS2 553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.